ODT Odonate Therapeutics Inc.

35.01
-0.16  -0%
Previous Close 35.17
Open 35.14
Price To Book 11.22
Market Cap 936,995,597
Shares 26,763,656
Volume 12,867
Short Ratio
Av. Daily Volume 113,179

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial enrolment to be completed 2H 2019 with data due 2020.
Tesetaxel - CONTESSA
Metastatic breast cancer (MBC)
Phase 2 trial initiation announced March 4, 2019.
Tesetaxel - Contessa 2
Metastatic breast cancer (MBC)

Latest News

  1. Here's Why Odonate Therapeutics Stock Jumped 70.7% in June
  2. Weekly CEO Buys Highlight
  3. Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $20 million of Shares
  4. Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
  5. Odonate Therapeutics Announces Public Offering of Shares of Common Stock
  6. Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis
  7. Odonate Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
  8. Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
  9. Small Drug Stocks Outlook: Near-Term Prospects Encouraging
  10. Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019
  11. Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing
  12. Odonate Therapeutics Initiates CONTESSA TRIO
  13. Have Insiders Been Buying Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?
  14. Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
  15. Odonate Therapeutics Announces Initiation of CONTESSA 2, a Phase 2 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane